dc.creator | Kotsiou O.S., Gourgoulianis K.I., Daniil Z. | en |
dc.date.accessioned | 2023-01-31T08:44:46Z | |
dc.date.available | 2023-01-31T08:44:46Z | |
dc.date.issued | 2021 | |
dc.identifier | 10.1080/02770903.2020.1750629 | |
dc.identifier.issn | 02770903 | |
dc.identifier.uri | http://hdl.handle.net/11615/75210 | |
dc.description.abstract | The clinical phenotyping of severe asthma could improve treatment outcomes, quality of life, morbidity, and mortality of asthma patients. The growing availability of rich clinical data could provide opportunities to address a broad range of real-world questions regarding clinical phenotyping and effective therapeutic approaches of severe asthma. Accordingly, in this Letter to the Editor, we provide data relevant to constructing the clinical profile of a Greek severe asthma patient cohort who receive biological treatment. © 2020 Taylor & Francis Group, LLC. | en |
dc.language.iso | en | en |
dc.source | Journal of Asthma | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85083555472&doi=10.1080%2f02770903.2020.1750629&partnerID=40&md5=f17e2bd8d143adc7e7905a983b8ac411 | |
dc.subject | bronchodilating agent | en |
dc.subject | mepolizumab | en |
dc.subject | omalizumab | en |
dc.subject | antiasthmatic agent | en |
dc.subject | monoclonal antibody | en |
dc.subject | omalizumab | en |
dc.subject | adult | en |
dc.subject | allergic rhinitis | en |
dc.subject | Asthma Control Test | en |
dc.subject | biological therapy | en |
dc.subject | bronchiectasis | en |
dc.subject | clinical article | en |
dc.subject | clinical feature | en |
dc.subject | cohort analysis | en |
dc.subject | comorbidity | en |
dc.subject | comparative study | en |
dc.subject | controlled study | en |
dc.subject | demography | en |
dc.subject | disease control | en |
dc.subject | disease duration | en |
dc.subject | eosinophil count | en |
dc.subject | eosinophilia | en |
dc.subject | evidence based practice | en |
dc.subject | ex-smoker | en |
dc.subject | female | en |
dc.subject | forced expiratory volume | en |
dc.subject | gastroesophageal reflux | en |
dc.subject | Greece | en |
dc.subject | human | en |
dc.subject | Letter | en |
dc.subject | male | en |
dc.subject | medical history | en |
dc.subject | middle aged | en |
dc.subject | morbidity | en |
dc.subject | mortality | en |
dc.subject | non-smoker | en |
dc.subject | obese patient | en |
dc.subject | obesity | en |
dc.subject | phenotype | en |
dc.subject | quality of life | en |
dc.subject | retrospective study | en |
dc.subject | severe asthma | en |
dc.subject | total quality management | en |
dc.subject | treatment outcome | en |
dc.subject | asthma | en |
dc.subject | Anti-Asthmatic Agents | en |
dc.subject | Antibodies, Monoclonal, Humanized | en |
dc.subject | Asthma | en |
dc.subject | Humans | en |
dc.subject | Omalizumab | en |
dc.subject | Quality of Life | en |
dc.subject | Taylor and Francis Ltd. | en |
dc.title | Clinical profile of severe asthmatics receiving biological treatment: see behind the scenes | en |
dc.type | other | en |